Hossein Nazemiyeh

Dr. Hossein Nazemiyeh


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2016 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Open access
ENElham Nazemiyeh
Elham Nazemiyeh
MEMorteza Eskandani
Morteza Eskandani
HSHossein Sheikhloie
Hossein Sheikhloie
HNHossein Nazemiyeh
Hossein Nazemiyeh
Formulation and Physicochemical Characterization of Lycopene-Loaded Solid Lipid Nanoparticles

1 August 2014 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
MEMorteza Eskandani
Morteza Eskandani
HNHossein Nazemiyeh
Hossein Nazemiyeh

8 April 2015 in Pharmaceutical Biology
Verified
Journal Article
Closed access
PDF file
MEMorteza Eskandani
Morteza Eskandani
JBJaleh Barar
Jaleh Barar
JDJafar Ezzati Nazhad Dolatabadi
Jafar Ezzati Nazhad Dolatabadi
HHHamed Hamishehkar
Hamed Hamishehkar
HNHossein Nazemiyeh
Hossein Nazemiyeh
Context: Galbanic acid (GBA) is a sesquiterpene coumarin with different medicinal properties and anticancer effects. Objective: To improve the anticancer activities of GBA, in the current study, we aimed to fabricate GBA-loaded solid lipid nanoparticles (GBA-SLNs) and study their biological activities in vitro. Materials and methods: Hot homogenization was used for preparation of GBA-SLNs. The encapsulation efficiency (EE) and drug loading (DL) and in vitro release were determined. MTT, DAPI, DNA fragmentation, comet, and Anexin V apoptosis assays were used to compare the anti-cell proliferation and genotoxicity properties of GBA and GBA-SLNs against A549 cells and HUVEC to detect apoptosis and DNA damage in the final concentration of 100 µM after 48 h treatment. Results: Scanning electron microscopy (SEM) and particle size analysis showed spherical SLNs (92 nm), monodispersed distribution, and zeta potential of −23.39 mV. High EE (>98%) and long-term in vitro release were achieved. The stability of GBA-SLNs in aqueous medium was approved after 3 months in terms of size and polydispersity index. GBA was able to inhibit A549 growth with an IC50 value of 62 µM at 48 h. Although GBA-SLNs could also inhibit the growth rate of A549 cells, the effect is perceived after 48 h, as approved by the quantitative expression of Bcl-xL and Casp 9 genes, and also genotoxicity assays. Conclusion: Long-term apoptotic effect of GBA-SLNs compared with GBA may be due to the accumulation of GBA-SLNs in the tumor site because of deviant tumor pathology. Our data confirmed that SLNs could be exploited for sustained lipophilic GBA delivery.

1 March 2015 in Fitoterapia
Verified
Journal Article
Closed access
MEMorteza Eskandani
Morteza Eskandani
JAJalal Abdolalizadeh
Jalal Abdolalizadeh
HHHamed Hamishehkar
Hamed Hamishehkar
HNHossein Nazemiyeh
Hossein Nazemiyeh
JBJaleh Barar
Jaleh Barar

1 June 2017 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
MEMorteza Eskandani
Morteza Eskandani
SVSomayeh Vandghanooni
Somayeh Vandghanooni
JBJaleh Barar
Jaleh Barar
HNHossein Nazemiyeh
Hossein Nazemiyeh
YOYadollah Omidi
Yadollah Omidi

1 April 2019 in Fitoterapia
Verified
Journal Article
Closed access
MBMir Babak Bahadori
Mir Babak Bahadori
SVSomayeh Vandghanooni
Somayeh Vandghanooni
LDLeila Dinparast
Leila Dinparast
MEMorteza Eskandani
Morteza Eskandani
SASeyed Abdulmajid Ayatollahi
Seyed Abdulmajid Ayatollahi
HNHossein Nazemiyeh
Hossein Nazemiyeh